貨號(hào)：5011， LIPID In Vivo Transfection Kit, 1.5 mL （30 injections）￥12530元

貨號(hào)：5021,， POLYMER In Vivo Transfection Kit, 1.5 mL （30 injections） ￥13090元
貨號(hào)：5031 ,，NANOPARTICLE In Vivo Transfection Kit, 1.5 mL （30 injections） ￥13370元
貨號(hào)：5041， PEG-Liposome In Vivo Transfection Kit, 1.5 mL （30 injections） ￥13650元
貨號(hào)：5051,PANCREAS-targeted In Vivo Transfection Reagent - 1.5 mL（30 injections）￥13930元
貨號(hào)：5061 LIVER-targeted In Vivo Transfection Reagent - 1.5 mL （30 injections） ￥13930元
貨號(hào)：5

IN VIVO TRANSFECTION KITS: PEG-Liposome, Nanoparticle, Polymer, Lipid, Tissue-targeted

• Cationic lipid liposome-based siRNA and plasmid DNA in vivo delivery reagent
• Efficient delivery to the liver, pancreas, kidney, and certain tumor types via systemic administration
• Complete product support information is available at: LIPID In Vivo Transfection Kit

Figure 1. Systemic administration （i.v.） of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

 

Figure 2. Intratumoral administration （i.t.） of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

 

POLYMER-based In Vivo Transfection Kit for Rodents （Mouse, Rat）

• Biodegradable polymer-based in vivo reagent
• Efficient delivery to the lung, liver, kidney, and spleen via systemic administration
• Complete product support information is available at: POLYMER In Vivo Transfection Kit

Figure 3. Systemic administration （i.v.） of Polymer-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

Figure 4. Intratumoral administration （i.t.） of Polymer-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

 

NANOPARTICLE-based In Vivo Transfection Kit for Rodents （Mouse, Rat）

• Nanoparticle-based reagent
• Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration
• Complete product support information is available at: NANOPARTICLE In Vivo Transfection Kit

Figure 5. Systemic administration （i.v.） of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

Figure 6. Intratumoral administration （i.t.） of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

 

PEG-Liposome In Vivo Transfection Kit for Rodents （Mouse, Rat）

• PEGylated liposome based reagent
• Efficient delivery to the spleen, kidney, pancreas, liver, and multiple tumor types via systemic administration
• Complete product support information is available at: PEG-Liposome In Vivo Transfection Kit

Figure 7. Systemic administration （i.v.） of Liposome-PEG based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

Figure 8. Intratumoral administration （i.t.） of Liposome-PEG based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD （n=6）.

 

Tissue-targeted In Vivo Transfection Reagents for Rodents （Mouse, Rat）:

• LIVER-targeted in vivo reagent
• KIDNEY-targeted in vivo reagent
• PANCREAS-targeted in vivo reagent